secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001628280-24-022762
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027
--------------------------------------------------------------------------------

- Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.
- Net loss $121.3M includes $79.3M loss from excess of warrant fair value over private placement proceeds and $27.5M acquired IPR&D expense.
- Closed private placement for up to $185M gross; initial $115.6M received; warrants classified as liability with $194.9M fair value.
- Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026; trial to start this year.
- Strategic review underway for quisovalimab (AVTX-002) and AVTX-008 programs; no revenue in Q1 2024 vs $475K a year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/0001628280-24-022762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/avtx-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-022762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer